These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 26458165)
21. Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders. Zundler S; Neurath MF Immunol Rev; 2017 Jul; 278(1):263-276. PubMed ID: 28658546 [TBL] [Abstract][Full Text] [Related]
22. New targets for mucosal healing and therapy in inflammatory bowel diseases. Neurath MF Mucosal Immunol; 2014 Jan; 7(1):6-19. PubMed ID: 24084775 [TBL] [Abstract][Full Text] [Related]
23. Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease. Bilal M; Nunes LV; Duarte MTS; Ferreira LFR; Soriano RN; Iqbal HMN Mar Drugs; 2021 Mar; 19(4):. PubMed ID: 33808253 [TBL] [Abstract][Full Text] [Related]
24. Treg subsets in inflammatory bowel disease and colorectal carcinoma: Characteristics, role, and therapeutic targets. van Herk EH; Te Velde AA J Gastroenterol Hepatol; 2016 Aug; 31(8):1393-404. PubMed ID: 26990130 [TBL] [Abstract][Full Text] [Related]
25. Gut-lung crosstalk in pulmonary involvement with inflammatory bowel diseases. Wang H; Liu JS; Peng SH; Deng XY; Zhu DM; Javidiparsijani S; Wang GR; Li DQ; Li LX; Wang YC; Luo JM World J Gastroenterol; 2013 Oct; 19(40):6794-804. PubMed ID: 24187454 [TBL] [Abstract][Full Text] [Related]
31. Mathematical model of the roles of T cells in inflammatory bowel disease. Lo WC; Arsenescu RI; Friedman A Bull Math Biol; 2013 Sep; 75(9):1417-33. PubMed ID: 23760658 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis. Siegmund B; Zeitz M Rocz Akad Med Bialymst; 2004; 49():22-30. PubMed ID: 15631310 [TBL] [Abstract][Full Text] [Related]
33. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies. Van Assche G; Vermeire S; Rutgeerts P Gastroenterol Clin North Am; 2006 Dec; 35(4):743-56. PubMed ID: 17129811 [TBL] [Abstract][Full Text] [Related]
34. Emerging therapeutic targets and strategies in Crohn's disease. Furfaro F; Fiorino G; Allocca M; Gilardi D; Danese S Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):735-44. PubMed ID: 26766496 [TBL] [Abstract][Full Text] [Related]
35. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Waldner MJ; Neurath MF Semin Immunol; 2014 Feb; 26(1):75-9. PubMed ID: 24447345 [TBL] [Abstract][Full Text] [Related]
36. Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. Di Sabatino A; Rovedatti L; Kaur R; Spencer JP; Brown JT; Morisset VD; Biancheri P; Leakey NA; Wilde JI; Scott L; Corazza GR; Lee K; Sengupta N; Knowles CH; Gunthorpe MJ; McLean PG; MacDonald TT; Kruidenier L J Immunol; 2009 Sep; 183(5):3454-62. PubMed ID: 19648266 [TBL] [Abstract][Full Text] [Related]
37. The role of macrophages in inflammatory bowel diseases. Heinsbroek SE; Gordon S Expert Rev Mol Med; 2009 May; 11():e14. PubMed ID: 19439108 [TBL] [Abstract][Full Text] [Related]